Linked Life Data

8536548

Source:http://linkedlifedata.com/resource/pubmed/id/8536548

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1996-2-7
pubmed:abstractText
In recent years, several biosynthetic hexa- and heptapeptides, as well as nonpeptide bezolactam derivatives, have been found to be potent growth hormone (GH) secretagogues. They act synergistically with GH-releasing hormone (GHRH) but via different receptors, and are GHRH dependent. All are active when administered intravenously, orally or subcutaneously. Short and long term experience in adults and children has proven that these drugs evoke the metabolic changes induced by GH and insulin-like growth factor-1 (IGF-1), including acceleration of growth velocity in children. With the exception of a partial downregulation phenomenon, no adverse effects have been reported so far. This new class hormone-like drugs acting GH secretagogues may have immense clinical potential.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0012-6667
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
595-601
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Growth hormone secretagogues. Clinical experience and therapeutic potential.
pubmed:affiliation
Sackler School of Medicine, Tel-Aviv University, Israel.
pubmed:publicationType
Journal Article, Review